NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
Authors:
- 1 January 2013
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 23 (1) , 48-62
Abstract
No abstract availableKeywords
Funding Information
- Minneapolis Medical Research Foundation
- National Cancer Institute (R01CA152105, R01CA115399, R21CA143887)
- Leukemia and Lymphoma Society
This publication has 48 references indexed in Scilit:
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myelomaHaematologica, 2010
- An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaBlood, 2008
- Original CIN: reviewing roles for APC in chromosome instabilityJournal of Cell Biology, 2008
- Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKKGenes & Development, 2008
- β-Catenin is a Nek2 substrate involved in centrosome separationGenes & Development, 2007
- The molecular classification of multiple myelomaBlood, 2006
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006
- Nek2 kinase in chromosome instability and cancerCancer Letters, 2006
- Mad2 and BubR1 Function in a Single Checkpoint Pathway that Responds to a Loss of TensionMolecular Biology of the Cell, 2002
- Bcl-2 family proteins as targets for anticancer drug designOncogene, 2000